South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
OpenAI Rejects Apple Trade Secret Theft Claims 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
Add as a preferred source on Google
NEW ORLEANS, March 28, 2018 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc. (Nasdaq:SLDB), if they purchased the Company’s shares between January 25, 2018, and March 14, 2018 (the “Class Period”) or in its January 25, 2018 initial public offering (“IPO”). This action is pending in the United States District Court for the District of Massachusetts.
What You May Do
If you purchased shares of Solid Biosciences and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-sldb/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 28, 2018.
About the Lawsuit
Solid Biosciences and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On January 30, 2018, a report co-authored by a former scientific advisor of the Company revealed risks of high systemic dosing using the Company’s delivery system, AAV or adeno-associated virus, for its lead drug candidate SGT-001. Then, on March 14, 2018, the Company disclosed a clinical hold placed on the SGT-001 trial by the FDA relating to adverse events.
On this news, the price of Solid Biosciences’ shares plummeted over 60% to $9.32/share on March 15, 2018.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
206 Covington St.
Madisonville, LA 70447
